SLC5A2 and hydrops fetalis: A meta-analysis by Aimo et al. showed that sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy was not associated with a significantly lower risk of CV death or HF hospitalizations compared to vericiguat, sacubitril, or valsartan.